pimodivir pimodivir pimodivir (vx-787, jnj-63623872) is an antiviral drug which was developed as a treatment for influenza. it acts as an inhibitor of influenza virus polymerase basic protein 2, and has shown promising results in phase ii clinical trials. however, in late 2021, janssen announced that the clinical development of pimidivir had been halted due to lack of benefit over standard of care. pimodivirclinical datatrade namespimodivirlegal statuslegal status us: investigational new drug identifiers iupac name (2s,3s)-3-pyridin-3-yl)pyrimidin-4-yl]amino]bicyclooctane-2-carboxylic acid cas number1629869-44-8pubchem cid67286591uniidfc121mxc3chemical and physical dataformulac20h19f2n5o2molar mass399.4 g·mol−13d model (jsmol)interactive image smiles o=c(o)1c2ccc(cc2)1nc1nc(-c2cc3ncc(f)cc23)ncc1f inchi inchi=1s/c20h19f2n5o2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16h,1-4h2,(h,23,24)(h,28,29)(h,25,26,27)/t9?,10?,15-,16-/m0/s1key:jgpxdnksixazeq-sbbzocnpsa-n